GREENWICH LIFESCIENCES, INC. Retained Earnings
GREENWICH LIFESCIENCES, INC. (GLSI) had Retained Earnings of -$96.74 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$96.74M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$92.79M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$87.14M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$77.59M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$96.74M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$92.79M 10-Q · filed 2026-06-04 | |
| 2025-12-31 | -$87.14M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$77.59M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$73.44M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$69.41M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | -$67.78M 10-K · filed 2026-06-01 | -$66.15M 10-K · filed 2025-04-15 |
| 2024-09-30 | -$58.11M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$55.44M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$52.84M 10-Q · filed 2024-05-20 | |
| 2023-12-31 | -$50.36M 10-K · filed 2025-04-15 | |
| 2023-09-30 | -$47.62M 10-Q · filed 2023-10-19 | |
| 2023-06-30 | -$45.23M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | -$43.60M 10-Q · filed 2023-05-22 | |
| 2022-12-31 | -$41.47M 10-K · filed 2024-04-15 | |
| 2022-09-30 | -$38.68M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$36.36M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$35.62M 10-Q · filed 2022-05-20 | |
| 2021-12-31 | -$33.65M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$31.29M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$30.42M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | -$29.67M 10-Q · filed 2021-05-20 | |
| 2020-12-31 | -$29.08M 10-K · filed 2022-03-21 | |
| 2020-09-30 | -$27.93M 10-Q · filed 2020-11-16 | |
| 2019-12-31 | -$27.21M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |